2023-09-012024-08-312024-08-31false13912941GLOBAL HEALTH CONSORTIUM LTD2025-02-2672200falseiso4217:GBPxbrli:pure139129412023-09-01139129412024-08-31139129412023-09-012024-08-31139129412022-09-01139129412023-08-31139129412022-09-012023-08-3113912941bus:SmallEntities2023-09-012024-08-3113912941bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3113912941bus:AbridgedAccounts2023-09-012024-08-3113912941bus:PrivateLimitedCompanyLtd2023-09-012024-08-3113912941core:WithinOneYear2024-08-3113912941core:AfterOneYear2024-08-3113912941core:WithinOneYear2023-08-3113912941core:AfterOneYear2023-08-3113912941core:ShareCapital2024-08-3113912941core:SharePremium2024-08-3113912941core:RevaluationReserve2024-08-3113912941core:OtherReservesSubtotal2024-08-3113912941core:RetainedEarningsAccumulatedLosses2024-08-3113912941core:ShareCapital2023-08-3113912941core:SharePremium2023-08-3113912941core:RevaluationReserve2023-08-3113912941core:OtherReservesSubtotal2023-08-3113912941core:RetainedEarningsAccumulatedLosses2023-08-3113912941core:LandBuildings2024-08-3113912941core:PlantMachinery2024-08-3113912941core:Vehicles2024-08-3113912941core:FurnitureFittings2024-08-3113912941core:OfficeEquipment2024-08-3113912941core:NetGoodwill2024-08-3113912941core:IntangibleAssetsOtherThanGoodwill2024-08-3113912941core:ListedExchangeTraded2024-08-3113912941core:UnlistedNon-exchangeTraded2024-08-3113912941core:LandBuildings2023-08-3113912941core:PlantMachinery2023-08-3113912941core:Vehicles2023-08-3113912941core:FurnitureFittings2023-08-3113912941core:OfficeEquipment2023-08-3113912941core:NetGoodwill2023-08-3113912941core:IntangibleAssetsOtherThanGoodwill2023-08-3113912941core:ListedExchangeTraded2023-08-3113912941core:UnlistedNon-exchangeTraded2023-08-3113912941core:LandBuildings2023-09-012024-08-3113912941core:PlantMachinery2023-09-012024-08-3113912941core:Vehicles2023-09-012024-08-3113912941core:FurnitureFittings2023-09-012024-08-3113912941core:OfficeEquipment2023-09-012024-08-3113912941core:NetGoodwill2023-09-012024-08-3113912941core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3113912941core:ListedExchangeTraded2023-09-012024-08-3113912941core:UnlistedNon-exchangeTraded2023-09-012024-08-3113912941core:MoreThanFiveYears2023-09-012024-08-3113912941core:Non-currentFinancialInstruments2024-08-3113912941core:Non-currentFinancialInstruments2023-08-3113912941dpl:CostSales2023-09-012024-08-3113912941dpl:DistributionCosts2023-09-012024-08-3113912941core:LandBuildings2023-09-012024-08-3113912941core:PlantMachinery2023-09-012024-08-3113912941core:Vehicles2023-09-012024-08-3113912941core:FurnitureFittings2023-09-012024-08-3113912941core:OfficeEquipment2023-09-012024-08-3113912941dpl:AdministrativeExpenses2023-09-012024-08-3113912941core:NetGoodwill2023-09-012024-08-3113912941core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3113912941dpl:GroupUndertakings2023-09-012024-08-3113912941dpl:ParticipatingInterests2023-09-012024-08-3113912941dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3113912941core:ListedExchangeTraded2023-09-012024-08-3113912941dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3113912941core:UnlistedNon-exchangeTraded2023-09-012024-08-3113912941dpl:CostSales2022-09-012023-08-3113912941dpl:DistributionCosts2022-09-012023-08-3113912941core:LandBuildings2022-09-012023-08-3113912941core:PlantMachinery2022-09-012023-08-3113912941core:Vehicles2022-09-012023-08-3113912941core:FurnitureFittings2022-09-012023-08-3113912941core:OfficeEquipment2022-09-012023-08-3113912941dpl:AdministrativeExpenses2022-09-012023-08-3113912941core:NetGoodwill2022-09-012023-08-3113912941core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3113912941dpl:GroupUndertakings2022-09-012023-08-3113912941dpl:ParticipatingInterests2022-09-012023-08-3113912941dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3113912941core:ListedExchangeTraded2022-09-012023-08-3113912941dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3113912941core:UnlistedNon-exchangeTraded2022-09-012023-08-3113912941core:NetGoodwill2024-08-3113912941core:IntangibleAssetsOtherThanGoodwill2024-08-3113912941core:LandBuildings2024-08-3113912941core:PlantMachinery2024-08-3113912941core:Vehicles2024-08-3113912941core:FurnitureFittings2024-08-3113912941core:OfficeEquipment2024-08-3113912941core:AfterOneYear2024-08-3113912941core:WithinOneYear2024-08-3113912941core:ListedExchangeTraded2024-08-3113912941core:UnlistedNon-exchangeTraded2024-08-3113912941core:ShareCapital2024-08-3113912941core:SharePremium2024-08-3113912941core:RevaluationReserve2024-08-3113912941core:OtherReservesSubtotal2024-08-3113912941core:RetainedEarningsAccumulatedLosses2024-08-3113912941core:NetGoodwill2023-08-3113912941core:IntangibleAssetsOtherThanGoodwill2023-08-3113912941core:LandBuildings2023-08-3113912941core:PlantMachinery2023-08-3113912941core:Vehicles2023-08-3113912941core:FurnitureFittings2023-08-3113912941core:OfficeEquipment2023-08-3113912941core:AfterOneYear2023-08-3113912941core:WithinOneYear2023-08-3113912941core:ListedExchangeTraded2023-08-3113912941core:UnlistedNon-exchangeTraded2023-08-3113912941core:ShareCapital2023-08-3113912941core:SharePremium2023-08-3113912941core:RevaluationReserve2023-08-3113912941core:OtherReservesSubtotal2023-08-3113912941core:RetainedEarningsAccumulatedLosses2023-08-3113912941core:NetGoodwill2022-09-0113912941core:IntangibleAssetsOtherThanGoodwill2022-09-0113912941core:LandBuildings2022-09-0113912941core:PlantMachinery2022-09-0113912941core:Vehicles2022-09-0113912941core:FurnitureFittings2022-09-0113912941core:OfficeEquipment2022-09-0113912941core:AfterOneYear2022-09-0113912941core:WithinOneYear2022-09-0113912941core:ListedExchangeTraded2022-09-0113912941core:UnlistedNon-exchangeTraded2022-09-0113912941core:ShareCapital2022-09-0113912941core:SharePremium2022-09-0113912941core:RevaluationReserve2022-09-0113912941core:OtherReservesSubtotal2022-09-0113912941core:RetainedEarningsAccumulatedLosses2022-09-0113912941core:AfterOneYear2023-09-012024-08-3113912941core:WithinOneYear2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113912941core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3113912941core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3113912941core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3113912941core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3113912941core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3113912941bus:Director12023-09-012024-08-3113912941bus:Director22023-09-012024-08-31

GLOBAL HEALTH CONSORTIUM LTD

Registered Number
13912941
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

GLOBAL HEALTH CONSORTIUM LTD
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

DIGHE, Shashank Sham
PATWARDHAN, Sudhanshu Ramesh

Registered Address

C/O Xeinadin First Floor Secure House
Lulworth Close
Chandler's Ford
SO53 3TL

Registered Number

13912941 (England and Wales)
GLOBAL HEALTH CONSORTIUM LTD
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets31,9442,611
1,9442,611
Current assets
Debtors475,7955,766
Cash at bank and on hand257,049292,015
332,844297,781
Prepayments and accrued income-5,187
Creditors amounts falling due within one year5(49,822)(72,554)
Net current assets (liabilities)283,022230,414
Total assets less current liabilities284,966233,025
Net assets284,966233,025
Capital and reserves
Called up share capital1,0001,000
Profit and loss account283,966232,025
Shareholders' funds284,966233,025
The financial statements were approved and authorised for issue by the Board of Directors on 26 February 2025, and are signed on its behalf by:
PATWARDHAN, Sudhanshu Ramesh
Director
Registered Company No. 13912941
GLOBAL HEALTH CONSORTIUM LTD
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings5
2.Average number of employees

20242023
Average number of employees during the year11
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 September 233,333
At 31 August 243,333
Depreciation and impairment
At 01 September 23722
Charge for year667
At 31 August 241,389
Net book value
At 31 August 241,944
At 31 August 232,611
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables60,000-
Amounts owed by group undertakings15,6945,694
Other debtors10172
Total75,7955,766
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables2777,812
Amounts owed to related parties4,812280
Taxation and social security43,65363,174
Other creditors-139
Accrued liabilities and deferred income1,0801,149
Total49,82272,554
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
6.Related party transactions
At the year-end the company owed Director Dr Sudhanshu Patwardhan £4,812.
7.Parent-subsidiary relationships
At the year-end the company was owed £15,694 by the subsidiary company NTX Limited